Australia markets close in 6 hours 1 minute

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.4300+0.0202 (+4.93%)
At close: 04:00PM EDT
0.4100 -0.02 (-4.65%)
After hours: 07:57PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 21.59M
Enterprise value 50.94M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.66
Price/book (mrq)N/A
Enterprise value/revenue 3.65
Enterprise value/EBITDA -2.06

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-95.93%
S&P500 52-week change 3-9.13%
52-week high 331.2400
52-week low 30.3300
50-day moving average 30.6360
200-day moving average 32.5126

Share statistics

Avg vol (3-month) 313.94M
Avg vol (10-day) 33.38M
Shares outstanding 552.02M
Implied shares outstanding 6N/A
Float 832.02M
% held by insiders 12.59%
% held by institutions 123.28%
Shares short (30 May 2022) 42.78M
Short ratio (30 May 2022) 40.31
Short % of float (30 May 2022) 47.73%
Short % of shares outstanding (30 May 2022) 45.34%
Shares short (prior month 28 Apr 2022) 4620.9k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -256.16%
Operating margin (ttm)-271.72%

Management effectiveness

Return on assets (ttm)-89.52%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)15.64M
Revenue per share (ttm)1.23
Quarterly revenue growth (yoy)72.10%
Gross profit (ttm)11.24M
EBITDA -42.46M
Net income avi to common (ttm)-35.71M
Diluted EPS (ttm)-2.8000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.14M
Total cash per share (mrq)0.18
Total debt (mrq)38.48M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.55
Book value per share (mrq)-1.23

Cash flow statement

Operating cash flow (ttm)-54.01M
Levered free cash flow (ttm)-43.12M